medical communications and marketing expertise

+ 44 (0)1477 549 652  e:
Pivotal 4pharma Blog

Cancer marketing San Antonio 2011

< Go back to main blog page

Welcome to 2012! (27/01/12)
A Happy New Year to all our friends and colleagues. Already the first few weeks of 2012 have passed, and we hope you are all fully recharged and feeling positive about the year ahead – even in these challenging and testing times for the Pharma industry. We would like to thank all our clients for their continued support during 2011.

2011 was another successful year for Pivotal 4pharma, we continued to gain new clients and expanded our service offer beyond the breast cancer disease area (albeit still predominantly within the oncology area) and were commissioned for different and new types of projects.

In 2011, Tim joined the International Society for Medical Publication Professionals (ISMPP), and attended the 2011 European Meeting in Cheshire. It was good to see many familiar faces and friends from the past. Since moving on from a Global Publications role in 2003, the industry has undergone dramatic change, particularly from a regulatory and transparency perspective, and the European conference provided a great opportunity to get up-to-speed with the current challenges. Certainly being back amongst the publications community has ‘whet’ the appetite for more, and Publications Strategy and Management will remain one of the services offered by Pivotal 4pharma.

In order to stay on top of developments and advances in the breast cancer area, Tim continues to attend relevant breast cancer congresses, and went to the St Gallen Early Breast Cancer meeting in March 2011 and the San Antonio Breast Cancer Symposium (SABCS) in December 2011. The San Antonio meeting still remains the premier breast cancer congress, covering both early and metastatic disease and basic and translational research. The meeting continues to expand in content, with the pre-meeting educational sessions now becoming a regular feature –the symposium is essentially a 4.5 day meeting. SABCS was very well attended and appeared to attract a similar number of delegates as in previous years.

SABCS 2011 featured a number of trials with data being presented for the first time. The data grabbing most attention were those from BOLERO-2, the trial investigating the efficacy and safety of everolimus + exemestane versus exemestane alone in postmenopausal women with metastatic breast cancer whose disease progressed whilst receiving non-steroidal aromatase inhibitor – presented by Professor Hortobagyi, the BOLERO-2 trial showed a ‘highly’ significant improvement in time to disease progression for the combination arm. Another combination regimen showing a significant improvement in disease progression in postmenopausal women was the combination of fulvestrant 250 mg + anastrozole, which led to a significant improvement in progression-free survival compared to anastrozole alone in the SWOG S0226 First-Line trial. Another trial well worthy of mention was the CLEOPATRA trial, a trial investigating ‘dual HER2’ blockade with pertuzumab and trastuzumab added to docetaxel, compared with trastuzumab + docetaxel combination therapy – the trial arm including the ‘dual HER2’ blockade led to a 6.1 month improvement in progression-free survival, and also showed a strong trend to improved overall survival.

If anyone would like further details on the above presentations, or in fact any others presented at SABCS, please contact us.

As mentioned previously, during 2011 Pivotal 4pharma also delivered a number of projects outside of the breast cancer area - new therapy areas being prostate cancer, lung cancer, oncology diagnostics and rheumatoid arthritis with a variety of projects which ranged from workshop programme development to literature reviews, data assessment and opportunity evaluation. The general pharma and breast cancer expertise developed by Tim during his time with AstraZeneca and Pivotal 4pharma, is very much transferable across the oncology disease area as a whole. To this end Pivotal 4pharma are currently considering some ‘subtle’ changes to our business focus which will be reflected in our website - although the breast cancer area will remain an area of major expertise and knowledge, we will be looking to broaden our services to the wider oncology area.

The start of 2012 has been very encouraging for Pivotal 4pharma in terms of new business gained and that currently in the pipeline, with projects both in and outside of the breast cancer area currently ongoing. However we are always very happy to discuss potential new projects, so please give us a call if you foresee any potential projects on the horizon, either short-term or further out in the future. Maybe you can join our growing list of satisfied customers.

We hope to see many of you at the forthcoming European Breast Cancer Conference (March 20-24th) in Vienna.

All the best to you all, and wishing you a happy and successful 2012.

“Tim is very diplomatic and has good project management and organizational skills.”

Professor Anthony Howell
Pivotal 4pharma provides strategic and tactical medical communications and marketing expertise.